Page updated ·next FDA decision on the calendar·Data as of Nov 14, 2026 7:42 PM ET
Price into the decision (T-120)
Daily close, T-120 (7/31/24) through T+5. Run-up high $4.09 on 8/7/24, low $1.93 on 1/14/25 (T-120 to T-1). FDA decision 1/15/25. Historical price action, not a forecast.
Decision facts
FDA decision date2025-01-15
DrugDehydraTECH-liraglutide - (GLP-1-H25-5). (Pilot Study #5)
Was DehydraTECH-liraglutide - (GLP-1-H25-5). (Pilot Study #5) approved by the FDA?
Yes. The approval of the application for DehydraTECH-liraglutide - (GLP-1-H25-5). (Pilot Study #5) was announced on January 15, 2025; pdufa.bio holds no FDA record stating the exact day the FDA acted. The primary source is linked on this page.
What was DehydraTECH-liraglutide - (GLP-1-H25-5). (Pilot Study #5) under FDA review for?
The application covered Obesity. The FDA approved the application on January 15, 2025.
How did LEXX stock react to the FDA decision?
On the decision day LEXX moved -1.6%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.